
The findings on treatment-resistant Klebsiella pneumoniae were “the biggest concern” among all the data collected on superbugs in Europe over the past year, Christian Giske, who leads this work at ECDC, told a press briefing.
It’s one example of the dangers posed by antimicrobial resistance — the ability of bacteria and fungi to evolve to be resistant to drugs designed to destroy them — which is estimated to kill 35,000 people in the EU, Iceland and Norway every year. For Europe, this is a “major public health threat,” Giske said.
Despite progress in some areas, the latest reports show the EU is still far from reaching its 2030 targets to reduce rates of drug-resistant infections. Among the challenges is the limited number of new drugs available to treat such infections.
The news comes as Europe's new pharmaceutical legislation is set to be signed into law in December and includes measures to boost the discovery and development of new antibiotics — through a market monopoly perk for industry and a push for steady payment models for countries to buy them.
Harder to tackle
Given that it spreads between patients, tackling the surging rates of Klebsiella requires stronger infection prevention and control measures in hospitals, the ECDC warns. This includes strengthening hand hygiene, ensuring correct use of personal protective equipment like gloves, and effective environmental cleaning and disinfection.
And while similar measures have helped to significantly cut EU rates of the better-known hospital-acquired superbug, MRSA, for Klebsiella, missing even the tiniest surface can lead to the bacteria spreading.